1. Home
  2. MI vs PRLD Comparison

MI vs PRLD Comparison

Compare MI & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NFT Limited

MI

NFT Limited

N/A

Current Price

$0.71

Market Cap

58.3M

ML Signal

N/A

Logo Prelude Therapeutics Incorporated

PRLD

Prelude Therapeutics Incorporated

N/A

Current Price

$3.54

Market Cap

69.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MI
PRLD
Founded
2009
2016
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Catalog/Specialty Distribution
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
58.3M
69.1M
IPO Year
2022
2020

Fundamental Metrics

Financial Performance
Metric
MI
PRLD
Price
$0.71
$3.54
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$4.00
AVG Volume (30 Days)
9.8K
304.4K
Earning Date
01-01-0001
06-17-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
23.21
EPS
N/A
N/A
Revenue
N/A
$12,140,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
73.43
52 Week Low
$1.57
$0.61
52 Week High
$6.70
$4.19

Technical Indicators

Market Signals
Indicator
MI
PRLD
Relative Strength Index (RSI) 16.84 69.26
Support Level N/A $0.99
Resistance Level $2.85 $4.19
Average True Range (ATR) 0.46 0.37
MACD -0.38 0.07
Stochastic Oscillator 0.30 96.86

Price Performance

Historical Comparison
MI
PRLD

About MI NFT Limited

NFT Ltd operates an online electronic platform for offering and trading artwork. Through its platform, the company allows artists/art dealers/owners to access a much bigger art trading market where artists can engage with a wide range of investors. Its platform also invests in high-end artwork accessible to ordinary people without financial resources. The company's trading platforms comprise the sale of calligraphies and paintings, jewelry, and precious stones. It generates revenue in the form of services in connection with the offering and trading of artwork on its system, consisting of listing fees, trading commissions, and management fees.

About PRLD Prelude Therapeutics Incorporated

Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.

Share on Social Networks: